The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Antares Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.72M | Series A-2 | 6/10/2025 | $139.29M | $289.7M | $1.00 | Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, Cormorant Asset Management, Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, Willett Advisors | |||||
| BioIntellisense | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $308.33M | Series C | 12/19/2025 | $5.43M | $76.82M | $0.88 | Undisclosed Investors | |||||
| Calibrate | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $97.15M | Series B | 8/25/2021 | $76.9M | $382.73M | $5.35 | Founders Fund, Tiger Global Management, Optum Ventures, Threshold Ventures, Forerunner Ventures, Redesign Health | |||||
| Cerebral | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $25M | Series D | 9/12/2025 | $25M | $407.5M | $2.50 | Undisclosed Investors | |||||
| CoRegen | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $131.81M | Series B-1 | 10/28/2025 | $13.5M | $431.58M | $18.00 | Undisclosed Investors | |||||
| Culture | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $142.12M | Series C-2 | 12/16/2025 | $20.52M | $60.79M | $0.29 | Northpond Ventures, Synthesis Capital, S32, Cultivian Sandbox | |||||
| Detect | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $77.02M | Series A-1 | 7/29/2026 | $31.99M | $118.22M | $1.22 | Undisclosed Investors | |||||
| Diverge Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $107.37M | Series A-4 | 9/30/2026 | $54.97M | $319.36M | $176.74 | Undisclosed Investors | |||||
| Ensoma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250.75M | Series B-1 | 9/22/2025 | $45.2M | $281.79M | $1.09 | Gilead, 5AM Ventures, Catalio Capital Management, Cormorant Asset Management, Delos Capital, F-Prime Capital, Gates Foundation, Hanwha Impact Partners, Mirae Asset Financial Group, Qatar Investment Authority, RTW, Solasta Ventures, SymBiosis, Viking Global Investors | |||||
| Flagler Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $62.75M | Series B | 8/11/2026 | $50M | $238.83M | $10.39 | Bessemer Venture Partners, SignalFire, Alumni Ventures, Streamlined, 186 Ventures, PROOF, Tribeca Venture Partners, Offscript | |||||
| Flare Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $290.35M | Series C | 6/30/2026 | $85M | $188.49M | $0.37 | Third Rock Ventures, Nextech Invest, Pfizer, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, Eventide Asset Management | |||||
| Geneoscopy | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.58M | Series C | 1/8/2025 | $79.05M | $447.85M | $4.13 | Bio-Rad Laboratories, Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, NT Investments, Granger Management, Mercy Health, Tri Locum Partners | |||||
| Kareo | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $136.5M | Series H | 10/9/2018 | $10M | $414.8M | $6.86 | Undisclosed Investors | |||||
| Quanta Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.34M | Series D | 6/24/2026 | $76.19M | $253.34M | $1.44 | Avidity Partners, Sofinnova Investments, Vida Ventures, Surveyor Capital, Longitude Capital, BVF Partners, AbbVie Ventures, GC&H Investments, WS Investment Company | |||||
| Ratio Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $151.27M | Series C | 7/31/2026 | $70M | $398.34M | $43.69 | Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, Wasatch Group | |||||
| Regard | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $81.87M | Series B-1 | 7/11/2024 | $55.75M | $350.42M | $5.73 | Oak HC/FT, Cedars-Sinai Health Ventures, TenOneTen, Calibrate Ventures, Techstars | |||||
| restor3d | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.97M | Series B-1 | 8/22/2025 | $65M | $265.79M | $2.60 | Partners Group | |||||
| SchoolCare | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $71.1M | Series A-2 | 5/11/2020 | $3.35M | $62.32M | $1.37 | Undisclosed Investors | |||||
| SetPoint Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $302.51M | Series D | 10/28/2025 | $115.5M | $471.52M | $1.51 | Elevage Medical Technologies, Ally Bridge Group, Northwell Health, SPRIG Equity, Norwest Venture Partners, New Enterprise Associates, Viking Global Investors, Action Potential Venture Capital, Abbott, Boston Scientific, Euclidean Capital, Richard King Mellon Foundation, Morgenthaler Ventures, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Gilmartin Capital, Midas Capital | |||||
| Sirona | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $142.05M | Series D | 10/15/2026 | $40M | $183.24M | $3.99 | -- | |||||
| Tizona Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $95.24M | Series B-3 | 1/3/2019 | $15M | $173.78M | $1.60 | AbbVie | |||||
| Accelus | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $6.08M | Series 2 | 5/29/2025 | $1.75M | $45.61M | $1.00 | Concord Health Partners | |||||
| Alveus Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $202.01M | Series A | 2/24/2026 | $197M | $290.11M | $20.00 | New Rhein Healthcare Investors, Andera Partners, Omega Funds, Sanofi Capital, Kurma Partners, Avego Management, Jeito Capital, Novo Holdings, Agent Capital, Seroba Lifesciences, Global BioAccess Fund | |||||
| Ansun Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $165.2M | Series B | 8/15/2018 | $100M | $466.82M | $1.49 | Lilly Asia Ventures, Matrix Partners China, Yuanming Capital, Lyfe Capital, 3E Bioventures | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.